26
Jul
2010
Mirina Corp.: Series A $3.9M
Posted in I - Series A, Q - 2Q10, R - NORTH WEST, X - Oncology, X - RNAi, XX - WA
Mirina (Seattle, WA) a development-stage biotechnology company focused on miRNA therapeutics for oncology and metabolic disorders, closed a $3.9M Series A financing, bringing the total round to $7.5M. Participants include Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.
16
Apr
2010
Achaogen, Inc. : Series C $56M
Posted in I - Series C, Q - 2Q10, R - WEST, X - Antibacterial, X - MDR, XX - CA
Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.
12
Apr
2010
Bind Biosciences, Inc.: Series C $11M
Posted in I - Series C, Q - 1Q10, R - NORTH EAST, X - Oncology, X - THx Delivery, X - Therapeutic Platform, XX - MA
Bind Biosciences (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on differential medicinal nanoengineered delivery of targeted therapeutics and controlled drug exposure to diseased tissue for various cancers, closed an $11M Series C financing. Participants have included DHK Investments, ARCH Venture Partners, Flagship Ventures, NanoDimension and Polaris Venture Partners.
29
Jan
2010
Receptos, Inc.: Series A $25M
Posted in I - Series A, Q - 4Q09, R - WEST, X - Autoimmune, X - GPCR, X - Immunology, XX - CA
Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb
27
Jan
2010
Pulmatrix, Inc.: Series B $30.2M
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA
Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]
26
Jan
2010
Fate Therapeutics, Inc.: Series B $30M
Posted in I - Series B, Q - 4Q09, R - WEST, X - Stem Cell, XX - CA
Fate Therapeutics (La Jolla, CA) a pre-clinical biopharma company focused on developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate tissue regeneration and blocking cancer growth, closed a $30M Series B financing. Participants include OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming [...]
OnBioVC PARTNERS
-
Where is OnBioVC Content Consumed?
